Ikarian-Capital

Filing Details

13F-HR2025-03-31
Report Date
2025-03-31
Filing Date
2025-05-15
Total Holdings
141
Total Value
710178588
Accession Number
0001420506-25-001276
Form Type
13F-HR
Manager Name
Ikarian-Capital
Data Enrichment
96% identified
135 identified6 unidentified

Holdings

141 positions • $710.2M total value
Manager:
Search and click to pin securities to the top
Page 3 of 8
Trevi Therapeutics, Inc.
Shares:575.0K
Value:$3.6M
% of Portfolio:0.5% ($3.6M/$710.2M)
578784100
Shares:322.7K
Value:$3.6M
% of Portfolio:0.5% ($3.6M/$710.2M)
Janux Therapeutics, Inc.
Shares:129.7K
Value:$3.5M
% of Portfolio:0.5% ($3.5M/$710.2M)
Eledon Pharmaceuticals, Inc.
Shares:1.0M
Value:$3.5M
% of Portfolio:0.5% ($3.5M/$710.2M)
Scholar Rock Holding Corp
Shares:100.0K
Value:$3.2M
% of Portfolio:0.5% ($3.2M/$710.2M)
uniQure N.V.
Shares:300.0K
Value:$3.2M
% of Portfolio:0.4% ($3.2M/$710.2M)
CUMBERLAND PHARMACEUTICALS INC
Shares:740.0K
Value:$3.1M
% of Portfolio:0.4% ($3.1M/$710.2M)
TEVA PHARMACEUTICAL INDUSTRIES LTD
Shares:200.0K
Value:$3.1M
% of Portfolio:0.4% ($3.1M/$710.2M)
Keros Therapeutics, Inc.
Shares:274.0K
Value:$2.8M
% of Portfolio:0.4% ($2.8M/$710.2M)
Kymera Therapeutics, Inc.
Shares:100.0K
Value:$2.7M
% of Portfolio:0.4% ($2.7M/$710.2M)
Apogee Therapeutics, Inc.
Shares:70.7K
Value:$2.6M
% of Portfolio:0.4% ($2.6M/$710.2M)
ABEONA THERAPEUTICS INC.
Shares:533.6K
Value:$2.5M
% of Portfolio:0.4% ($2.5M/$710.2M)
CYBIN INC.
Shares:397.2K
Value:$2.5M
% of Portfolio:0.4% ($2.5M/$710.2M)
iBio, Inc.
Shares:599.9K
Value:$2.4M
% of Portfolio:0.3% ($2.4M/$710.2M)
10919W405
Shares:65.4K
Value:$2.4M
% of Portfolio:0.3% ($2.4M/$710.2M)
Evolus, Inc.
Shares:193.3K
Value:$2.3M
% of Portfolio:0.3% ($2.3M/$710.2M)
Dyne Therapeutics, Inc.
Shares:187.0K
Value:$2.0M
% of Portfolio:0.3% ($2.0M/$710.2M)
Relay Therapeutics, Inc.
Shares:743.3K
Value:$1.9M
% of Portfolio:0.3% ($1.9M/$710.2M)
Lexeo Therapeutics, Inc.
Shares:550.0K
Value:$1.9M
% of Portfolio:0.3% ($1.9M/$710.2M)
Kodiak Sciences Inc.
Shares:649.5K
Value:$1.8M
% of Portfolio:0.3% ($1.8M/$710.2M)